Proposed model for the protective mechanism of CPE against CKD-induced HAS
The proposed model for the protective mechanism of CPE against CKD-induced HAS. Left: 5/6 NFx induces RAAS overactivation, leading to an increase in Ang II. This results in the upregulation of AT1R and the downregulation of AT2R and Mas1. These alterations establish a vasopressive state, reducing the GFR and allowing for the accumulation of uremic compounds. The sustained production of ROS, LP, and PC surpasses endogenous antioxidant systems, causing oxidative stress-mediated cellular damage and inflammation in the endothelium and smooth vascular muscle of the arteriole. This inflammatory environment triggers the expression of iNOS and the further oxidation of NO· to ONOO−, contributing to nitrative stress. Simultaneously, cellular damage leads to depletion in the glomeruli filtering barrier by diminishing nephrin and podocin, allowing for the occurrence of proteinuria. The persistent overactivation of RAAS increases the peripheral swiftness of arteries, culminating in endothelial dysfunction and the establishment of SAH. This perpetuates the decline in the GFR and the progression of CKD. Upon oral-gavage administration, CPE undergoes digestion, releasing chromo-peptides and PEB. These components mitigate ROS-mediated cellular damage through scavenging. Additionally, CPE prevents dysregulation in vasomodulation by normalizing the expression of AT1R, AT2R, and the Mas1/Akt1/eNOS pathway. Through these mechanisms, CPE maintains kidney function and prevents the establishment of SAH. CKD: Chronic kidney disease; BUN: Blood ureic nitrogen; GFR: Glomerular filtration rate; RAAS: Renin angiotensin aldosterone system; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MAP: Mean arterial pressure; ROS: Reactive oxygen species; LP: Lipid peroxidation; PC: Protein carbonylation; CPE: C-phycoerythrin; PEB: Phycoerythrobilin. Dash line represents reduced pathway; bold line represents increased pathway. Created with Biorender.com
Publication
C-Phycoerythrin Prevents Chronic Kidney Disease-Induced Systemic Arterial Hypertension, Avoiding Oxidative Stress and Vascular Dysfunction in Remanent Functional Kidney (2024) Oscar Iván Florencio-Santiago, et al. Mar Drugs. 2024 Aug;22(8). Figure: F7.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | CPE | CPE | ncbigene_symbol | CPE | 1363 |
| Homo sapiens | Primates | ACE2 | ACE2 | ncbigene_symbol | ACE2 | 59272 |
| Homo sapiens | Primates | AngII | ANG2 | ncbigene_synonym | ANGPT2 | 285 |
| Homo sapiens | Primates | AngII | ANG2 | ncbigene_synonym | VPS51 | 738 |
| Homo sapiens | Primates | Mas | MAS | ncbigene_synonym | MAS1 | 4142 |
| Homo sapiens | Primates | AKT | AKT | ncbigene_synonym | AKT1 | 207 |
| Homo sapiens | Primates | AKT | AKT | famplex_relations | AKT2 | 208 |
| Homo sapiens | Primates | AKT | AKT | famplex_relations | AKT3 | 10000 |
| Homo sapiens | Primates | eNOS | ENOS | ncbigene_synonym | NOS3 | 4846 |
| Homo sapiens | Primates | eNOS | ENOS | ncbigene_synonym | ENO4 | 387712 |
| Homo sapiens | Primates | Nephrin | NEPHRIN | ncbigene_synonym | NPHS1 | 4868 |
| Homo sapiens | Primates | AT1R | AT1R | ncbigene_synonym | AGTR1 | 185 |
| Homo sapiens | Primates | Mas1 | MAS1 | ncbigene_synonym | PMPCB | 9512 |
| Homo sapiens | Primates | L-Arg | LARG | ncbigene_synonym | ARHGEF12 | 23365 |
| Homo sapiens | Primates | +GFR | GFR | ncbigene_synonym | RAPGEF5 | 9771 |
| Homo sapiens | Primates | SBP | SBP | ncbigene_synonym | SHBG | 6462 |
| Homo sapiens | Primates | SBP | SBP | ncbigene_synonym | CCHCR1 | 54535 |
| Homo sapiens | Primates | DBP | DBP | ncbigene_symbol | DBP | 1628 |
| Homo sapiens | Primates | DBP | DBP | ncbigene_synonym | GC | 2638 |
| Homo sapiens | Primates | DBP | DBP | ncbigene_synonym | HSD17B4 | 3295 |
| Homo sapiens | Primates | MAP | MAP | ncbigene_synonym | SGSM3 | 27352 |
| Homo sapiens | Primates | TMAP | TMAP | ncbigene_synonym | CKAP2 | 26586 |
| Homo sapiens | Primates | SAH | SAH | ncbigene_synonym | ACSM3 | 6296 |
| Homo sapiens | Primates | .PC | PC | ncbigene_symbol | PC | 5091 |
| Homo sapiens | Primates | INOS | INOS | ncbigene_synonym | NOS2 | 4843 |
| Homo sapiens | Primates | INOS | INOS | ncbigene_synonym | ISYNA1 | 51477 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| Angiotensinogen | Angiotensinogen | chebi:2720 | ||
| Ang II | ang II | chebi:48432 | ||
| Angiotensinogen | Angiotensinogen | chebi:2720 | ||
| Mas | MAs | chebi:25427 | ||
| mage | MAGE | chebi:75883 | ||
| GSSG | GSSG | (2S,2'S)-5,5'-[disulfanediylbis({(2R)-3-[(carboxymethyl)amino]-3-oxopropane-1,2-diyl}imino)]bis(2-amino-5-oxopentanoic acid) | chebi:17858 | |
| GSH | GSH | L-gamma-glutamyl-L-cysteinylglycine | chebi:16856 | |
| L-Arg | L-Arg | L-arginine | chebi:16467 | |
| ROS | ROS | chebi:26523 | ||
| ROS | ROS | chebi:26523 | ||
| Creatinine | creatinine | creatinine | chebi:16737 | |
| DBP | DBP | dibutyl benzene-1,2-dicarboxylate | chebi:34687 | |
| SAH | SAH | S-(5'-deoxyadenosin-5'-yl)-L-homocysteine | chebi:16680 | |
| ROS | ROS | chebi:26523 | ||
| MAP | MAP | (6alpha)-6-methyl-3,20-dioxopregn-4-en-17-yl acetate | chebi:6716 | |
| GSH | GSH | L-gamma-glutamyl-L-cysteinylglycine | chebi:16856 | |
| Ang II | ang II | chebi:48432 | ||
| ROS | ROS | chebi:26523 | ||
| DBP | DBP | dibutyl benzene-1,2-dicarboxylate | chebi:34687 | |
| SAH | SAH | S-(5'-deoxyadenosin-5'-yl)-L-homocysteine | chebi:16680 | |
| MAP | MAP | (6alpha)-6-methyl-3,20-dioxopregn-4-en-17-yl acetate | chebi:6716 | |
| Creatinine | creatinine | creatinine | chebi:16737 |
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|---|---|---|---|
| Proteinuria | proteinuria | proteinuria | DOID:576 |